Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Comment by zxcvbnnmon Mar 02, 2018 9:27am
88 Views
Post# 27650495

RE:This link might explain why you are nervous Newcoin...

RE:This link might explain why you are nervous Newcoin...Thank you for positing the out of date information which has been well factored into the share price years ago.

It is actually good to know that the RBP transaction was ended up being paid in all shares. So according to Terra Nova, if former management was ochestrating everything, they also suffered signficantly now due to the sharp decrease in the share price. So lose lose for everyone. 

However, the purchase of RBP had created the billing division, and has generated the company additional $500k+ stable revenue every quarter. So minimum $2M+ revenue every year as of status quo, not to mention the growing and expanding potential and opportunities. 

The significant share price decrease on June 29, 2016 had actually made this undervalued opportunity more attractive. Imagine overstating RBP's revenue from $2M+ to up to $3M warrants this much overreaction?

Old management is out now, or even they were still hidden shareholders because of RBP, they are suffering as much as we suffer. Brann has 10%, and he bought via his hard earned real money at over 100% of the current share price.

Will be illogical that everyone is not on the same page now to turn around the company. It is obvious that the billing division is much more lucrative than the loan division with low cost basis, high revenue potential, whereas for the loan division, you just earn interest differentials from your cash, a low-yeild dividend business. 


Bullboard Posts